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Diffuse Alveolar Hemorrhage
Moo Suk Park, M.D., Ph.D.
Division of Pulmonology, Department of Internal Medicine, Severance Hospital, Institute of Chest Diseases, Yonsei University 
College of Medicine, Seoul, Korea
Diffuse alveolar hemorrhage (DAH) is a life-threatening and medical emergency that can be caused by numerous 
disorders and presents with hemoptysis, anemia, and diffuse alveolar infiltrates. Early bronchoscopy with 
bronchoalveolar lavage is usually required to confirm the diagnosis and rule out infection. Most cases of DAH 
are caused by capillaritis associated with systemic autoimmune diseases such as anti-neutrophil cytoplasmic 
antibody-associated vasculitis, anti-glomerular basement membrane disease, and systemic lupus erythematosus, but 
DAH may also result from coagulation disorders, drugs, inhaled toxins, or transplantation. The diagnosis of DAH 
relies on clinical suspicion combined with laboratory, radiologic, and pathologic findings. Early recognition is 
crucial, because prompt diagnosis and treatment is necessary for survival. Corticosteroids and immunosuppressive 
agents remain the gold standard. In patients with DAH, biopsy of involved sites can help to identify the cause 
and to direct therapy. This article aims to provide a general review of the causes and clinical presentation of 
DAH and to recommend a diagnostic approach and a management plan for the most common causes.
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Introduction
  Diffuse alveolar hemorrhage (DAH) is a life-threat-
ening condition caused by a variety of disorders asso-
ciated with hemoptysis, anemia, diffuse lung infiltration, 
and acute respiratory failure. DAH originates from the 
pulmonary microcirculation, including the alveolar ca-
pillaries, arterioles, and venules and is usually diffuse, 
but may also be focal. DAH should be distinguished 
from other causes of pulmonary hemorrhage caused by 
localized pulmonary abnormalities and the bronchial 
circulation. Early bronchoscopy with bronchoalveolar 
lavage (BAL) is generally required to confirm the diag-
nosis of DAH and rule out infection.
  Systemic vasculitis is one of the most common causes 
of DAH and can be pathologically defined by the pres-
ence of cellular inflammation, vessel destruction, tissue 
necrosis, and eventually, organ dysfunction. The lung 
is the site frequently involved in systemic vasculitis. The 
clinical features of each patient's disease are determined 
by the site, size, and type of vessel involved.
  Because the clinical presentation of the disease un-
derlying DAH is highly variable, the identification of a 
cause is very difficult. Thus, particular attention should 
be paid to the pattern of findings or clinical scenarios. 
The diagnosis of DAH relies on the clinician's recog-
nition combined with clinical, laboratory, radiologic, 
and pathologic features.
  Early recognition is crucial because prompt diagnosis 
and treatment are required for survival. Despite ad-
vances in the identification and management of DAH, 
it remains a condition with high morbidity and 
mortality. This article aims to provide a general review 
Review
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Table 1. Causes of diffuse alveolar hemorrhage
Cause
With pathologic capillaritis
  Primary idiopathic small vessel vasculitis
    Wegener's granulomatosis
    Churg-Strauss syndrome
    Microscopic polyangiitis
    Isolated pauci-immune pulmonary capillaritis
    Idiopathic pauci-immune glomerulonephritis
  Primary immune complex-mediated vasculitis
    Goodpasture's syndrome
    Henoch-Schonlein purpura
  Secondary vasculitis
    Classic autoimmune diseases
    Systemic lupus erythematosus
    Rheumatoid arthritis
    Antiphospholipid antibody syndrome
    Mixed connective tissue disease
    Polymyositis/dermatomyositis
  Essential cryoglobulinemia
  Behcet's disease
  Acute lung transplantation rejection
  Autologous bone marrow transplantation
  Drug-induced (e.g., chemotherapeutic agents, 
propylthiouracil)
Without pathologic capillaritis (bland pulmonary hemorrhage)
  Idiopathic pulmonary hemosiderosis 
  Coagulopathy: anticoagulants, anti-platelet, thrombolytics, 
DIC
  Mitral stenosis, pulmonary veno-occlusive disease
  Toxin or inhalation injury (isocyanates, crack cocaine, retinoic
acid)
  Goodpasture's syndrome
  Systemic Lupus erythematosus
  Drug-associated disease (amiodarone, penicillamine, 
nitrofurantoin)
Diffuse alveolar damage and other conditions
  Bone marrow transplantation, inhalation
  Cytotoxic drug therapy, radiation therapy
  ARDS
  Other conditions (infection, malignancy, embolism, etc.)
DIC: disseminated intravascular coagulation; ARDS: acute respi-
ratory distress syndrome.
of the clinical presentation and causes of DAH and to 
recommend a diagnostic approach and management 
plan for the most common causes.
Definition
  DAH is a distinct clinicopathologic syndrome of pul-
monary hemorrhage that originates from the pulmonary 
microcirculation, including the alveolar capillaries, arte-
rioles, and venules. It presents with hemoptysis, ane-
mia, diffuse lung infiltration, and acute respiratory 
failure. The diagnosis is confirmed by the observation 
of the accumulation of red blood cells (RBCs), fibrin, 
or hemosiderin-laden macrophage in the alveolar space 
on pathologic biopsy1. Hemosiderin, a product of he-
moglobin degradation, appears at least 48–72 hours af-
ter bleeding and is helpful in distinguishing DAH from 
surgical trauma. Mild interstitial thickening, organizing 
pneumonia, or diffuse alveolar damage can also be 
seen2.
  DAH is associated with pulmonary capillaritis, bland 
pulmonary hemorrhage, diffuse alveolar damage, and 
miscellaneous histology. Pulmonary capillaritis is the 
most common finding3. Pulmonary capillaritis has a 
unique histopathologic appearance, consisting of an in-
terstitial neutrophilic predominant infiltration, fibrinoid 
necrosis of the alveolar and capillary walls, leukocyto-
clasis caused by systemic vasculitis, anti-glomerular 
basement membrane (GBM) disease, and classic auto-
immune disease2. The infiltrating neutrophils undergo 
cytoclasis and nuclear debris accumulates within the in-
terstitium, and there is a subsequent loss of the integrity 
of the alveolar capillary basement membrane. Systemic 
vasculitis can also involve the microcirculation. Pulmon-
ary capillaritis may also be a small vessel vasculitis lim-
ited to the lung. Pulmonary vasculitis refers to in-
flammation of the lung vessels of any size, whereas pul-
monary capillaritis is confined to the microcirculation of 
the lung3.
Etiology and Classification
  A number of diseases can cause DAH. In general, 
DAH occurs in three characteristic patterns which reflect 
the nature of the underlying vascular injury (Table 1). 
Any source of injury to the alveolar microcirculation can 
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theoretically cause alveolar hemorrhage4,5.
1. DAH associated with vasculitis or capillaritis
  Most cases of DAH are caused by pulmonary capillar-
itis and are closely associated with systemic vasculitis 
and findings such as anti-neutrophil cytoplasmic anti-
body (ANCA)-associated vasculitis, anti-GBM disease, 
systemic lupus erythematosus (SLE), and collagen vas-
cular diseases (CVDs). It is also seen with several other 
conditions, including the use of certain drugs and 
transplantation.
2. Bland pulmonary hemorrhage (without capillaritis 
or vasculitis)
  In this pattern, RBCs leak into the alveoli without any 
evidence of inflammation or destruction of the alveolar 
capillaries, venules, and arterioles. The epithelial lesions 
are usually microscopic and are scattered geographi-
cally. Anti-GBM diseases and SLE can induce both pul-
monary capillaritis and bland pulmonary hemorrhage.
3. DAH associated with another process or condition
  In this third category of DAH, alveolar hemorrhage 
is caused by processes other than pulmonary vascular 
inflammation or the direct extravasation of RBCs, such 
as diffuse alveolar damage, inhalation, or cytotoxic drug 
therapy.
Clinical Presentations, Symptoms, and Signs
  DAH can be defined by the presence of hemoptysis, 
diffuse alveolar infiltrates, a drop in hematocrit, and hy-
poxemic respiratory failure. Hemoptysis may develop 
for a few hours or a few days, but up to one-third of 
patients do not have hemoptysis. The alveolar infiltrates 
can be unilateral, and a drop in hematocrit or hemoglo-
bin can be difficult to document. DAH may be pre-
sented in acute, subacute, or repetitive patterns with 
variable severity. Therefore, DAH must be considered 
in patients with otherwise unexplained alveolar infilt-
rates. Non-specific cough, dyspnea, chest pain, and fe-
ver may develop. Underlying systemic symptoms may 
also be present. Thus, a high index of clinical suspicion 
is essential. Two possible clinical scenarios are de-
scribed in the following sections4.
1. DAH with associated systemic symptoms and 
signs
  Certain clues from a patient's clinical history that 
should raise suspicion for DAH are: 1) recent infection 
suggesting Henoch-Schönlein purpura or cryoglobuline-
mic vasculitis, 2) use of a possibly offending drug such 
as an anticoagulant, D-penicillamine, nitrofurantoin, 
amiodarone, propylthiouracil, cocaine, or sirolimus, 3) 
exposure to toxic agents such as trimellitic anhydride, 
insecticides, or pesticides, or 4) a known co-morbid 
condition such as systemic vasculitis, CVD, mitral valve 
disease, or solid organ or stem cell transplantation4.
  Clinical scenarios suggestive of vasculitis are: 1) DAH, 
2) acute glomerulonephritis (GN), 3) pulmonary-renal 
syndrome, 4) deforming or ulcerating upper airway dis-
ease, 5) cavitary or nodular disease on chest imaging, 
6) palpable purpura, 7) mononeuritis multiplex, or 8) 
multisystem disease6.
  If sinus disease, skin manifestations, pulmonary pa-
renchymal nodules, and cavitary lesions coexist with 
positivity for anti-proteinase 3 (PR3) C-ANCA and biop-
sy-proven granuloma, then Wegener's granulomatosis 
(WG) should be considered. DAH with GN and skin 
manifestations, positivity for P-ANCA, and necrotizing 
non-granulomatous lesions on end-organ biopsy may 
lead to a diagnosis of microscopic polyangiitis (MPA). 
Churg-Strauss syndrome (CSS) should be considered if 
asthma, eosinophilia, pulmonary infiltrates, and DAH 
coexist. In young smokers with GN and DAH present-
ing as either bland alveolar hemorrhage or pulmonary 
capillaritis, Goodpasture's syndrome or anti-GBM dis-
ease are possible diagnoses.
2. DAH without systemic symptoms and signs
  When the above conditions have been considered but 
no suggestive findings are found, the following four 
conditions should be considered: 1) anti-GBM disease 
in limited pulmonary form or onset, for which positivity 
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Figure 1. Diagnostic approach in patients with diffuse alveolar hemorrhage. FOB: fiberoptic bronchoscopy; BAL: bronchio-
loalveolar lavage; Bx: biopsy; Cx: culture; DAH: diffuse alveolar hemorrhage; Dx: diagnosis; Hx: history; CHF: congestive
heart failure; MV: mitral valve; BM: bone marrow; ANA: anti-nuclear antibody; U/A: urinalysis; ANCA: anti-neutrophil cyto-
plasmic antibodies; RF: rheumatic factor; ESR: erythrocyte sedimentation rate; Cr: creatinine; GBM: glomerular basement
membrane; APL: anti-phospholipid; Ab: antibody.
to the antibody with linear deposits in the lungs would 
be diagnostic, 2) pulmonary-limited MPA, which would 
be positive for positive anti-myeloperoxidase (MPO) 
P-ANCA, 3) pauci-immune isolated pulmonary capillar-
itis, which would show evidence of neutrophilic pulmo-
nary capillaritis upon biopsy, or 4) idiopathic pulmo-
nary hemosiderosis, a diagnosis of exclusion, when the 
biopsy shows evidence of acute, subacute, and chronic 
bland DAH and no evidence of vasculitis in young age4.
Diagnostic Approach
  Since DAH represents a medical emergency, a thou-
ghtful and thorough approach to the diagnosis of DAH 
is critical to appropriate management. The diagnosis of 
DAH relies on the clinician's recognition combined with 
specific clinical, laboratory, radiologic, and pathologic 
features. The two important goals of the clinical evalua-
tion are: 1) establishing the diagnosis of DAH and 2) 
identifying the underlying cause7. Although individual 
cases of DAH may require modification, the recom-
mended approach is outlined in the following sections 
(Figure 1).
1. Careful history taking and physical examinations
  Careful attention should be given to the presence of 
symptoms such as hemoptysis, cough and dyspnea, and 
any pre-existing medical conditions. A detailed drug 
and occupational history should be taken. In patients 
who present with hemoptysis, focal sources of pulmo-
nary hemorrhage and upper airway and gastrointestinal 
bleeding sources must be excluded. Congestive heart 
failure, pneumonia, and other acute presentations of dif-
fuse parenchymal lung disease must be also consid-
ered1.
  A careful evaluation of the eyes for evidence of epis-
cleritis or retinal vasculitis, the nasopharynx for nasal 
septal erosion or saddle nose deformities, and the skin 
for leukocytoclastic vasculitis should be conducted. 
DAH may represent the primary manifestation of an un-
derlying systemic vasculitis or CVD, so the absence of 
historical or physical evidence should not eliminate 
Tuberculosis and Respiratory Diseases Vol. 74. No. 4, Apr. 2013
155
these as possible causes1.
2. Laboratory studies
  In initial diagnostic studies, culture of blood and oth-
er affected organs must be obtained to exclude infec-
tion. Although the findings are generally nonspecific, 
routine laboratory tests such as a complete blood count 
with differential, chemistry, liver tests, blood urea nitro-
gen, and creatinine should be obtained. An elevated er-
ythrocyte sedimentation rate and C-reactive protein are 
expected in active vasculitis but lack specificity. 
Urinalysis with microscopic examination should be ob-
tained in all patients. Proteinuria and microscopic hem-
aturia are common early findings in WG and MPA. 
Anti-GBM disease should be screened in all patients 
with DAH or a pulmonary-renal syndrome. In most pa-
tients with DAH, serum ANCA, anti-GBM antibodies, an-
tinuclear antibody (ANA), and anti-phospholipid anti-
bodies should be obtained.
  ANA and rheumatoid factor may be positive in pri-
mary vasculitis, but high titers and disease-specific anti-
bodies such as dsDNA, SS-A/SS-B, anti-ribonucleopro-
tein, and anti-JO-1 favor a CVD. Total IgE should be 
obtained when CSS is being considered. Complement 
(C3 and C4) should be obtained whenever SLE is in the 
differential6.
  C-ANCA is primarily associated with antibodies di-
rected against PR3. The P-ANCA pattern is observed in 
the context of antibodies directed against a wide variety 
of intracellular antigens; it is most commonly associated 
with MPO. C-ANCA is highly sensitive (90–95%) in ac-
tive, systemic WG, with a specificity of approximately 
90%. However, a positive P-ANCA lacks sensitivity and 
provides no more than suggestive evidence of CSS, 
MPA, or idiopathic pauci-immune GN because it can be 
found in a wide variety of settings, including rheuma-
toid arthritis and Goodpasture's syndrome6.
  In stable patients, the diffusion capacity for carbon 
monoxide can be measured and, if elevated, favors a 
diagnosis of DAH8. Recent alveolar hemorrhage in-
creases the diffusion capacity for carbon monoxide, 
whereas hemorrhage that occurs more than 48 hours 
before testing is unlikely to cause significant elevation.
3. Radiologic findings
  Plain chest X-rays and computed tomography scans 
often show abnormalities even in the absence of clin-
ically significant symptoms. Chest X-rays may show pat-
chy or diffuse alveolar opacities. Recurrent episodes of 
hemorrhage may lead to reticular interstitial opacities 
due to pulmonary fibrosis, usually with minimal honey-
combing. Computed tomography may show areas of 
consolidation interspersed with areas of ground-glass at-
tenuation and preserved normal areas. These findings 
are generally nonspecific. Cavities, nodules, and diffuse 
ground glass opacification with DAH is suspicious of 
vasculitis. Lymph node adenopathy is not a common 
finding and is more suggestive of infection or malig-
nancy4,6,9.
4. Bronchoscopy
  Early bronchoscopy is indicated in most patients who 
are suspected to have DAH. Bronchoscopy is used pri-
marily to document alveolar hemorrhage and exclude 
infection. A rising RBC count in sequential BAL aliquots 
from the same location is considered diagnostic of 
DAH. BAL specimens should be sent for routine bacte-
rial cultures and fungal, viral, and Pneumocystis carinii 
studies when indicated. The use of transbronchial biop-
sy (TBB) in patients with suspected DAH is con-
troversial2. Due to the small size of the specimens and 
the mechanical disruption of tissue architecture that 
generally occurs, TBB is rarely used in identifying the 
cause of DAH10.
5. Diagnostic biopsy
  Although a confident diagnosis may occasionally be 
made without tissue biopsy, diagnostic biopsy remains 
key to diagnosis. Diagnostic tissue may be obtained 
from easily accessible sites, such as the skin or upper 
airway lesions10.
  If systemic vasculitis, Goodpasture's syndrome, or 
CVD is suspected, renal biopsy is preferred and should 
be obtained immediately. In addition to conventional 
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histopathology, immunofluorescence (IF) and electron 
microscopy studies should be performed when appro-
priate. A renal biopsy with direct IF is usually helpful 
if there are laboratory abnormalities suggestive of renal 
insufficiency or GN. Light microscopy showing focal 
segmental necrotizing GN is not by itself sufficient to 
differentiate between the GN seen in WG, MPA, 
Goodpasture's syndrome, or SLE. However, direct IF 
will show clumpy immune complex deposition in SLE, 
linear immune complex deposition along the basement 
membranes in Goodpasture's syndrome, and scanty or 
no immune deposits in the pauci-immune GN typical 
of MPA or WG2.
  In patients in whom the diagnosis of DAH is still in 
question after a thorough clinical evaluation or in whom 
the underlying cause of DAH is still unclear after appro-
priate serologic testing, surgical biopsy should be 
entertained. When the lung is clinically involved, surgi-
cal lung biopsy almost always provides definitive patho-
logic evidence. Although useful in confirming DAH, sur-
gical lung biopsy is generally unable to identify the un-
derlying cause11. The biopsy samples should be proc-
essed so as to have tissues in saline for culture, frozen 
tissue for IF, and formalin-fixed tissue for standard hem-
atoxylin and eosin staining.
Treatment and Management
  Therapy for DAH consists of treating both the auto-
immune destruction of the alveolar capillary membrane 
and the underlying condition. Corticosteroids (CS) and 
immunosuppressive agents remain the gold standard for 
most patients. Recombinant-activated human factor VII 
seems to be a promising new therapy, but further evalu-
ation is needed.
  Immunosuppressive agents are the mainstay of ther-
apy for DAH, especially if associated with systemic or 
pulmonary vasculitis, Goodpasture's syndrome, or CVDs. 
Most experts recommend intravenous methylpredni-
solone (Solu-Medrol) at up to 500 mg every 6 hours, 
although lower doses seem to have similar efficacy, for 
4 or 5 days, followed by a gradual taper to maintenance 
doses of oral steroids4.
  Other immunosuppressive drugs such as cyclo-
phosphamide (CYC), azathioprine (AZA), methotrexate 
(MTX), mycophenolate mofetil (MMF), and etanercept 
may be used in DAH, especially in severe cases re-
fractory to first-line therapy with CS. Plasmapheresis 
(PE) is indicated for DAH associated with Goodpasture's 
syndrome or other vasculitic processes in which the tit-
ers of pathogenic immunoglobulins and immune com-
plexes are very high. 
  Before the institution of immunosuppressive therapy, 
patients with systemic vasculitis had a mortality rate of 
75%. CS therapy alone improved mortality, but the 
5-year mortality remained at 50%. A major breakthrough 
occurred when CYC was added to CS, which lowered 
the 5-year mortality to 12%12. Despite this impressive 
progress, the mortality of patients with systemic vasculi-
tis who receive treatment still remains high. Therefore, 
the goals of therapy in patients with systemic vasculitis 
are the prevention of disease-related mortality or mor-
bidity and the minimization of treatment-related compli-
cations.
1. General principles
  The backbone of therapy for vasculitis is the early 
identification of disease followed by the rapid initiation 
of disease control with immunosuppression. The se-
verity of the disease generally dictates the intensity of 
the initial treatment and the risk of complication. 
Therapy is often divided into two phases: An initial 
"remission-induction" phase controls active disease, and 
a "maintenance" phase, which uses less intensive ther-
apy, maintains disease remission while lowering the risk 
of adverse medication related events.
  Treatment recommendations depend on an accurate 
determination of disease severity. Although severity and 
prognosis are dependent on a number of factors, the 
most important of which seems to be the severity of 
disease activity as measured by the number of organ 
systems involved, the degree of renal disease, and the 
presence of DAH. Based on these associations, the 
European Vasculitis Study Group (EUVAS) has devised 
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Table 2. The severity of vasculitis and treatment options according to European vasculitis (EUVAS) grading
Clinical class End organ involvement Constitutional symptoms Renal function
Threatened vital 
organ function Treatment options
Limited No, only upper airway No Cr＜120μmol/L (1.4 mg/dL) No CS or MTX or AZA
Early Yes, but no functional Yes Cr＜120μmol/L (1.4 mg/dL) No CS＋CYC or MTX
 generalized  impairment
Active Yes, with significant Yes Cr＜500μmol/L (5.7 mg/dL) Yes CS＋CYC or RIT
 generalized  impairment
Severe Yes, immediate threat Yes Cr＞500μmol/L (5.7 mg/dL) Yes CS＋CYC or RIT＋PE
 of organ failure, DAH, CHF
Refractory Failed to respond Yes            Any Yes Consider investigational
 conventional therapy  agents
EUVAS: European Vasculitis Study Group; Cr: creatinine; CS: corticosteroid; MTX: methotrexate; AZA: azathioprine; CYC: cyclo-
phosphamide; RIT: rituximab; DAH: diffuse alveolar hemorrhage; CHF: congestive heart failure; PE: plasma exchange.
a clinically useful grading system (Table 2) in which the 
patient's disease is categorized as 1) limited, 2) early, 
generalized, 3) active, generalized, 4) severe, or 5) re-
fractory13,14.
2. Remission-induction therapy
  1) Limited disease: Limited disease refers to localized 
disease of the upper airway. These patients have no 
systemic symptoms, no impairment of end organ func-
tion, and no renal involvement. In this setting, therapy 
can often be limited to a single agent, such as CS, AZA, 
or MTX.
  2) Early, generalized disease: Early, generalized dis-
ease is differentiated from active generalized disease by 
the presence or absence of impaired organ function. 
Treatment recommendations for these two subsets have 
traditionally been similar, with CYC plus CS being the 
first-line therapy for both conditions. MTX is also an ac-
ceptable first-line therapy for early generalized disease, 
and, given the potentially more favorable side-effect 
profile, the combination of MTX plus CS is increasingly 
being used.
  3) Active, generalized disease: CYC plus CS has re-
mained the principal first-line therapy for the treatment 
of active, generalized vasculitis12. Recent evidence sug-
gests that pulsed intravenous CYC may be as effective 
as oral CYC while having fewer side effects.
  4) Severe disease: Severe disease is defined by the 
functional impairment of critical organs, such as severe 
renal disease (creatinine＞5.7 mg/dL), DAH, or other 
life-threatening disease. Recent studies suggest that pa-
tients with severe disease should receive a combination 
of CYC, CS, and PE therapy. The addition of PE therapy 
to the standard CYC plus CS regimen has been shown 
to be superior to high-dose, pulsed, intravenous steroids 
at restoring renal function in patients with severe renal 
impairment and DAH15. Additional therapy, described in 
a case report, for patients with intractable DAH include 
activated human factor VII, which was used to induce 
hemostasis16. As described in a case report, extracor-
poreal membrane oxygenation has also been used to 
buy time until the onset of action of other interven-
tions17.
  5) Refractory disease: Patients who have not re-
sponded to the aggressive use of cytotoxic agents, 
high-dose CS, or PE are deemed to have refractory 
disease. For this group, the physician must consider the 
use of novel or experimental agents. Treatments such 
as intravenous immunoglobulin, anti-tumor necrosis fac-
tor-α therapy with infliximab, T-cell depletion therapy 
with antithymocyte globulin, and B-cell depletion ther-
apy with rituximab (a monoclonal anti-CD20 antibody) 
have been used. In a recent series of 11 patients with 
active ANCA-associated vasculitis, rituximab was used to 
treat patients who had received maximal doses or had 
other contraindications to CYC therapy. Remission was 
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Table 3. Summary of clinical and laboratory findings for the common causes of diffuse alveolar hemorrhage 
WG MPA  CSS Goodpasture SLE IPH
Incidence, millions/yr  8.5–10.3  6.8–8.9  0.5–3.7  3.0–4.0 60–350 0.2–1.2
Age, yr 43 (median) 53 (median)    −  16–30 10–40   16
M:F   1.3:1    2:1    −    2:1  1:8   1:1
Lab findings
  Anti-GBM    −    −    −    ＋   −   −
  C-ANCA  ＋ (90%) Possible   Possible ± (10–15%) Rarely   −
  P-ANCA  ± (5–30%)  ＋ (50–75%) ＋ (35–75%)    −   ±   −
  ANA    −    −    −    − ＋ (90%)   −
  Eosinophilia Rare, mild Rare, mild Often, severe Rare, mild Possible Possible
Organ involvement, %
  Lungs  55–90  25–50    40  60–94 50–70  100
  DAH  17–50  10–50   Rare  80–94  4–20  100
  Diffuse infiltration   ＞15   ＞50  30–70  80–94 50–70 Possible
  Kidney  70–85  80–90    25  40–70 Often   −
Treatment
  CS＋CYC/AZ    ＋    ＋    ＋    ＋   ＋   ＋
  Plasmapheresis Possible Possible    −    ＋   ＋   −
WG: Wegener's granulomatosis; MPA: microscopic polyangiitis; CSS: Churg-Strauss syndrome; SLE: systemic lupus erythematous;
IPH: idiopathic pulmonary hemosiderosis; Anti-GBM: anti-glomerular basement membrane antibody; ANCA: anti-neutrophil cytoplasmic
antibody; ANA: antinuclear antibody; DAH: diffuse alveolar hemorrhage; CS: corticosteroid; CYC: cyclophosphamide; AZ: azathoprine.
induced in all 11 patients, and ANCA titers became un-
detectable in eight patients18.
3. Maintenance therapy
  Maintenance therapy used to maintain control of the 
disease requires less immunosuppression and should be 
associated with fewer and less severe adverse effects. 
After the induction of clinical remission with an agent 
such as CYC, patients generally convert to AZA or 
MTX19,20. Additional agents that have been used in se-
lect patients include MMF, leflunomide, and cyclo-
sporine. However, etanercept was not effective for the 
maintenance of disease remission in WG patients21. In 
the absence of a disease flare, maintenance therapy is 
generally continued for 12 to 18 months. A longer dura-
tion of therapy should be considered for patients at high 
risk for relapse.
Specific Disorders and Causes of DAH
  Table 3 summarizes the common causes and diag-
nostic features of DAH.
1. Wegener's granulomatosis
  WG is a systemic vasculitis that primarily affects mid-
dle-aged adults and is characterized by necrotizing gran-
ulomatous inflammation. In 1936, Wegener published a 
report on a new disease that would be differentiated 
from periarteritis nodosa. In 1954, Godman and Churg 
described a detailed diagnostic triad classic for Wegener's 
consisting of necrotizing granulomatous inflammation of 
the upper and lower respiratory tract, generalized ne-
crotizing vasculitis involving the small arteries and 
veins, and necrotizing GN22,23.
  Of the ANCA-associated vasculitis, WG is the most 
common. The upper and lower respiratory tracts are 
typically affected, with destruction of the nasal septum 
and sinuses and cavitating lesions in the lungs. Involve-
ment of the kidney is common, with histopathologic le-
sions of focal segmental necrotizing GN. The eyes, skin, 
and other organs may also be involved. Frequently, the 
complete triad is not present at initial presentation. The 
diagnosis of WG is commonly made serologically, with 
a positive C-ANCA. A positive C-ANCA or anti-PR3 is 
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found in 85% to 95% of active systemic disease but is 
less frequently seen (60–65% sensitive) in organ-limited 
disease and is even less common (40% sensitive) in 
remissions. Its specificity is approximately 90%6.
  In cases in which the diagnosis remains uncertain, 
surgical biopsy of the affected organs (primarily the 
lungs) may show typical necrotizing granulomatous 
lesions. DAH either can complicate an established case 
of WG or represent the initial manifestation of the 
disease. DAH is often subclinical and recurrent in WG. 
This pattern of frequently recurring DAH is seen with 
ANCA-associated vasculitis and CVD1.
  Treatment with high-dose CS and CYC is the initial 
therapy recommended for DAH that complicates WG. 
AZA may be substituted for CYC after remission. 
Intravenous immunoglobulin may be effective for per-
sistent disease. Mortality is considerable and most often 
caused by acute respiratory failure, renal failure, or su-
perimposed infection as a result of immunosuppressive 
therapy. Poor outcomes are correlated with advanced 
age, more severe renal impairment, alveolar hemor-
rhage, and anti-PR3 positivity.
2. Allergic Angitis with Granuloma (CSS)
  In 1951, Churg and Strauss reported a new entity sep-
arate from periarteritis nodosa presenting with fever, se-
vere asthma, and hypereosinophilia, with evidence of 
systemic vasculitis. The syndrome is characterized by 
the triad of 1) asthma, 2) hypereosinophilia, and 3) ne-
crotizing vasculitis. A three-phase presentation is also 
seen, with an initial atopy/sinusitis/asthma phase, fol-
lowed by an eosinophilic phase, and finally the vascu-
litic phase. Although DAH and GN may occur, they are 
much less common than in the other small-vessel 
vasculitides. ANCA positivity is seen less frequently than 
in WG, with a positive P-ANCA (or anti-MPO) seen in 
35% to 75% of patients with active disease. A positive 
C-ANCA has been described in up to 10% of patients. 
Necrotizing, small-vessel vasculitis and an eosinophil- 
rich cellular infiltrate with necrotizing granulomas are 
seen histopathologically22,23.
  The use of CS to treat asthma may delay the manifes-
tations of tissue eosinophilia and vasculitis until they are 
tapered. CSS generally responds well to CS. The role 
of cytotoxic agents such as CYC is not as clearly defined 
as in WG24,25.
3. Microscopic polyangiitis
  MPA is considered to be a small vessel variant of pol-
yarteritis nodosa. Distinguishing MPA from WG can be 
difficult because the clinical presentation, histopatho-
logic findings, and serologic findings can be similar. 
Occasionally, a diagnosis of MPA is ruled out after the 
development of the typical clinical and serologic fea-
tures of WG. The most consistent pathologic feature in 
MPA is a focal segmental necrotizing GN, also seen in 
WG, other vasculitides, Goodpasture's syndrome, and 
CVD1.
  GN with lung involvement is seen in up to 30% of 
patients with MPA. In patients who develop lung dis-
ease, DAH with pathologic capillaritis is the most com-
mon manifestation. Joint, skin, peripheral nervous sys-
tem, and gastrointestinal involvement are also relatively 
common. A positive serum P-ANCA (or MPO) strongly 
supports the diagnosis and can help distinguish MPA 
from WG. A positive P-ANCA is seen in 50% to 75% 
of patients and anti-MPO is seen in 35% to 65% of pa-
tients, whereas a positive C-ANCA is seen in 10% to 15% 
of patients. Focal, segmental necrotizing vasculitis and 
a mixed inflammatory infiltrate without granuloma are 
seen histopathologically6.
  Treatment with high-dose CS and CYC or AZA is 
recommended. PE is of unclear benefit. As in WG, in-
travenous immunoglobulin may be useful for resistant 
cases. Factor VIIa has also been used successfully26.
4. Isolated pulmonary capillaritis
  Occasional cases of DAH show no evidence of con-
comitant systemic involvement but show capillaritis 
upon histopathologic examination. Isolated pulmonary 
capillaritis appears to be small vessel vasculitis confined 
to the lungs. Some cases are associated with serum 
P-ANCA positivity, but most are pauci-immune. While 
isolated pulmonary capillaritis after treatment with 
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all-trans retinoic acid has been observed, most cases are 
sporadic. Although mechanical ventilation due to respi-
ratory failure is common, a positive response to CS and 
CYC has been reported. Most patients improve while 
on therapy, and recurrent disease is infrequent1,27.
5. Goodpasture's syndrome (anti-GBM disease)
  The diagnosis of Goodpasture's syndrome, or an-
ti-GBM disease, is reserved for cases of DAH and GN 
in which anti-GBM Ab (autoantibodies directed against 
the NC1 domain of the α3 chain of the type IV colla-
gen in the basement membrane) appears in the serum 
or tissue. The typical patient is a young male smoker, 
although elderly persons, women, and nonsmokers are 
also affected. DAH may be facilitated by alveolar per-
meability, which is increased in most smokers28.
  More than 90% of patients with Goodpasture's syn-
drome have serum anti-GBM Ab. In persons without cir-
culating antibody, the diagnosis may be confirmed by 
lung or preferably kidney biopsy demonstrating linear 
deposition of antibody along the alveolar or GBM that 
is visible by direct IF. However, in up to 10% of patients 
with Goodpasture's syndrome, DAH is present without 
renal involvement and is identical to isolated pulmonary 
capillaritis, and lung biopsy with IF studies can aid in 
the differentiation of the two diseases. Bland hemor-
rhage is the most common underlying histology, but 
pulmonary capillaritis is sometimes seen. In such cases, 
kidney biopsy still shows the typical linear antibody 
deposition. About 30% of anti-GBM positive sera have 
P-ANCA (MPO) and C-ANCA (PR3) also occurs29.
  Treatment of Goodpasture's syndrome requires a 
combination of CS, CYC or AZA, and PE. In the few 
cases with isolated DAH, treatment with CS alone may 
be effective. Cases of refractory, life-threatening Good-
pasture's syndrome have been reported to respond to 
MMF and rituximab. The 2-year survival rate in Good-
pasture's syndrome is approximately 50%1.
6. SLE and CVDs
  By far the most common underlying CVD in DAH is 
SLE. DAH, usually caused by pulmonary capillaritis, af-
fects 4% of patients with SLE but is life threatening 
when it occurs. In the majority of cases of DAH asso-
ciated with SLE, GN is also present, and 80% of these 
cases occur in young female patients with known SLE. 
In immunosuppressed patients with SLE, infectious 
pneumonia should be excluded as the cause of DAH. 
DAH is distinguished from acute lupus pneumonitis by 
sequential BAL. Acute lupus pneumonitis presents with 
similar clinical and radiographic features as DAH. 
However, it also has the systemic symptoms typical of 
an SLE flare and may be the only manifestation of the 
initial presentation of SLE. Direct IF examination of 
SLE-associated DAH reveals granular deposits of im-
munoglobulin and complement in the alveolar inter-
stitium and intra-alveolar blood vessels1,3.
  High-dose pulse methylprednisolone (1 g given in 
divided doses for 3 days) can be given to those with 
DAH or acute lupus pneumonitis. Anecdotally, the com-
bination of high-dose intravenous methylprednisolone 
and CYC is known to be the most effective combin-
ation. In refractory cases, PE has been used. The overall 
mortality rate for SLE-associated DAH is approximately 
50% and recurrences after treatment are frequent3.
  DAH has been described in rheumatoid arthritis, scle-
roderma, polymyositis, dermatomyositis, anti-phospholi-
pid antibody syndrome, and mixed connective tissue 
disease. Treatment options are similar to those outlined 
for DAH in SLE1.
7. Bone marrow transplantation (BMT)
  DAH occurs in approximately 5–20% of BMT recipi-
ents and the reported mortality rate ranges from 50% 
to 100%. Risk factors for the development of DAH in 
BMT recipients include older age, total body radiation, 
myeloablative conditioning regimens, and severe acute 
graft-vs-host disease. Dyspnea, fever, and cough are the 
most common complaints. Hemoptysis is less frequently 
observed in BMT recipients compared with other causes 
of DAH with a rate of approximately 15%. The patho-
genesis has yet to be clearly established, but it has been 
suggested that tissue injury, inflammation, and the asso-
ciated cytokine release play important roles. Lung biop-
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sy reveals diffuse alveolar damage and DAH. The ma-
jority of patients with DAH require mechanical ven-
tilation and CS is the mainstay of treatment, but its effec-
tiveness is still uncertain3.
Conclusion
  DAH is a clinicopathologic syndrome caused by 
many disorders and should be considered a life-threat-
ening event. Common causes of DAH are systemic vas-
culitis such as WG, CSS, and MPA, Goodpasture's syn-
drome, CVD, BMT, drugs, and idiopathic conditions. 
DAH should be suspected in any patient with alveolar 
infiltrates on chest X-ray, hypoxemia, anemia, and 
hemoptysis. Careful attention to the medical history, 
physical examination, and a targeted laboratory evalua-
tion often reveals the underlying cause. Patients sus-
pected to have DAH should generally undergo broncho-
scopy and BAL. In patients with evidence of DAH and 
renal involvement, kidney biopsy should be considered 
to identify the underlying cause and to direct therapy. 
A systematic approach to early recognition, establish-
ment of diagnosis, and aggressive treatment will likely 
decrease the morbidity and mortality associated with 
DAH.
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